PRESS RELEASES

Date Title View
Toggle Summary Chimerix to Present at Cowen and Company 2nd Annual Virtual Oncology Innovation Summit
DURHAM, N.C. , May 13, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer, and Mike Andriole, Chief Business and
View HTML
Toggle Summary Chimerix Reports First Quarter 2021 Financial Results and Provides Operational Update
– BCV PDUFA Date Set for July 7 and ONC201 Blinded Independent Central Review Expected in Second Half of 2021 – – DSTAT COVID 19 Trial Advances to Cohort 3 at Higher Dose – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a
View HTML
Toggle Summary Chimerix to Report First Quarter 2021 Financial Results and Provide an Operational Update on May 6, 2021
DURHAM, N.C. , April 29, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, May 6, 2021
View HTML
Toggle Summary Chimerix Appoints Vicki Vakiener to Board of Directors
DURHAM, N.C. , April 26, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the appointment of Vicki Vakiener to its Board of Directors, effective
View HTML
Toggle Summary Chimerix Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
DURHAM, N.C. , April 08, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced upcoming poster presentations at the American Association for Cancer Research
View HTML
Toggle Summary Chimerix to Present at Virtual H.C. Wainwright Global Life Sciences Conference
DURHAM, N.C. , March 02, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer, will participate in a pre-recorded
View HTML
Toggle Summary Chimerix Reports Promising Topline Results from First Cohort of a Randomized COVID-19 Trial with DSTAT
– Conference Call at 8:30 a.m. ET Today – DURHAM, N.C. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, reported topline results today from the first cohort of
View HTML
Toggle Summary Chimerix Reports Fourth Quarter and Year End 2020 Financial Results and Provides Operational Update
– Acquisition of Oncoceutics Adds Late-Stage Precision Oncology Pipeline – – Recently Completed Financing Supports Broad Investment Across Pipeline – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company
View HTML
Toggle Summary Chimerix to Report Fourth Quarter and Year End 2020 Financial Results and Provide an Operational Update on February 25, 2021
DURHAM, N.C. , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, February 25,
View HTML
Toggle Summary Chimerix Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
DURHAM, N.C. , Jan. 25, 2021 (GLOBE NEWSWIRE) -- Chimerix , Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced today the closing of its previously announced underwritten public offering of
View HTML